

SKELETAL MUSCLE HEALTH IN METABOLIC DISEASES



Editor:

Hiroaki Eshima

Bentham Books

Skeletal Muscle Health in Metabolic Diseases

Edited by

Hiroaki Eshima

*Department of International Tourism
Sports Tourism Course
Nagasaki International University
Nagasaki, Japan*

Ikuru Miura

*Faculty of Sports and Health Science
Fukuoka University
Fukuoka, Japan*

Yutaka Matsunaga

*Faculty of Human Health
Kurume University
Kurume, Japan*

&

Yuki Tomiga

*Faculty of Sports and Health Science
Fukuoka University
Fukuoka, Japan*

Skeletal Muscle Health in Metabolic Diseases

Editors: Hiroaki Eshima, Ikuru Miura, Yutaka Matsunaga & Yuki Tomiga

ISBN (Online): 978-981-5313-92-5

ISBN (Print): 978-981-5313-93-2

ISBN (Paperback): 978-981-5313-94-9

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 MUSCLE GLUCOSE METABOLISM IN METABOLIC DISEASES	1
<i>Hiroaki Eshima</i>	
INTRODUCTION	1
MUSCLE GLUCOSE TRANSPORTER IN OBESITY AND DIABETES	2
MUSCLE GLUCOSE TRANSPORTER IN EXERCISE	4
MUSCLE LIPID AND INSULIN RESISTANCE IN OBESITY AND DIABETES	6
CONCLUDING REMARKS	9
REFERENCES	9
CHAPTER 2 THE ROLE OF SKELETAL MUSCLES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE	16
<i>Ikuru Miura</i>	
INTRODUCTION	16
DEFINITION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)	17
MECHANISM OF ONSET AND PROGRESSION OF NASH (MASH): THE MULTIPLE PARALLEL HITS HYPOTHESIS	18
Relationship of Skeletal Muscle Mass and MASLD	19
Relationship of Skeletal Muscle Function and MASLD	21
MEDIATOR OF MUSCLE-LIVER AXIS	22
Insulin Resistance (IR)	22
Hyperammonemia	24
Deficiency of Vitamin D	25
Chronic Inflammation	25
Myokine	26
Myostatin/GDF-8	26
Irisin	27
Interleukin-6 (IL-6)	27
CONCLUSION	27
REFERNCES	28
CHAPTER 3 IMPACT OF NUTRITION AND EXERCISE ON CARBOHYDRATE METABOLISM	33
<i>Yutaka Matsunaga</i>	
INTRODUCTION	33
EXERCISE AND GLYCOGEN DEPLETION	34
Effects of Muscle Glycogen Depletion	35
Effects of Liver Glycogen Depletion	35
METHOD TO REDUCE GLYCOGEN DEPLETION	36
Carbohydrate Loading	36
Fat Adaptation	36
Exercise Training	37
GLYCOGEN RECOVERY AFTER EXERCISE	37
What to Ingest?	37
Regarding Quantity	38
Timing and Frequency	39
Digestion and Absorption	39

Combination of Nutrients	40
Energy Expenditure	41
METABOLIC DISEASE AND GLYCOGEN	41
CONCLUDING REMARKS	42
REFERENCES	42
CHAPTER 4 BRAIN HEALTH IN METABOLIC DISEASE AND EXERCISE	47
<i>Yuki Tomiga</i>	
INTRODUCTION	47
IMPAIRED BRAIN HEALTH IN METABOLIC DISEASE	48
IMPAIRED NEUROGENESIS AND MOLECULAR MECHANISMS IN THE BRAIN IN	
METABOLIC DISEASE	49
EXERCISE IN BRAIN HEALTH	51
EFFECTS OF MOLECULAR MECHANISMS OF EXERCISE ON COGNITIVE	
FUNCTIONS AND METABOLIC DISORDERS-RELATED BRAIN DYSFUNCTION	52
ROLE OF ORGAN CROSSTALK IN EXERCISE IN METABOLIC DISORDERS AND	
BRAIN HEALTH	53
CONCLUDING REMARKS	55
REFERENCES	56
CHAPTER 5 MUSCLE ATROPHY AND WEAKNESS IN METABOLIC DISEASE	62
<i>Hiroaki Eshima</i>	
INTRODUCTION	62
MUSCLE ATROPHY IN METABOLIC DISEASE	63
MUSCLE CONTRACTILE ADAPTATION IN METABOLIC DISEASE	64
CONCLUDING REMARKS	71
REFERENCES	71
CHAPTER 6 THE CELLULAR MECHANISM IN SKELETAL MUSCLE IN METABOLIC	
DISEASE: LIPID SPECIES AND OXIDATIVE STRESS	76
<i>Hiroaki Eshima</i>	
INTRODUCTION	76
LIPID SPECIES IN SKELETAL MUSCLE	77
NOVEL POTENTIAL MECHANISMS FOR OXIDATIVE STRESS IN METABOLIC	
DISEASE	79
CONCLUDING REMARKS	85
REFERENCES	85
SUBJECT INDEX	; 3

PREFACE

Metabolic diseases such as obesity and diabetes cause disruption of systemic energy metabolism and are major public health problems, affecting at least 2 billion people worldwide. The energy metabolism of the whole body is mainly regulated by skeletal muscle, liver, and brain. This book, entitled “Skeletal Muscle Health in Metabolic Disease”, aims to clarify organ and tissue alterations in metabolic diseases, such as obesity, diabetes, and fatty liver.

The book comprises six chapters. The first chapter gives a background of metabolic diseases that affect cellular mechanisms in muscle cells and muscle tissue, especially glucose metabolism in skeletal muscle.

The skeletal muscle and liver share functions as metabolic organs, contributing to systemic metabolic regulation through mutual cooperation. The second chapter discusses the latest findings on the crosstalk between metabolic dysfunction-associated steatotic liver disease (MASLD) and skeletal muscles, which starts and progresses in association with obesity and its associated systemic metabolic abnormalities.

The third chapter focuses on nutrition, especially carbohydrate metabolism. Lipids are stored in the body mainly in the form of triglycerides, whereas carbohydrates are primarily stored in the liver and skeletal muscles in the form of glycogen. Glycogen utilization has also been shown to increase during exercise. When glycogen is depleted, exercise performance is impaired. Therefore, carbohydrate metabolism is important for exercise and the maintenance of organ and tissue homeostasis.

Metabolic diseases are closely associated with brain health and noncommunicable diseases, including type 2 diabetes. By contrast, exercise exerts its beneficial effects on the brain by releasing bioactive substances. The fourth chapter presents how metabolic diseases affect brain health and how exercise mitigates these detrimental effects, focusing particularly on the molecular mechanisms in the brain.

The subsequent five and six chapters discuss muscle atrophy and weakness and cellular mechanisms in metabolic disease. Muscle oxidative stress has been implicated in lipid species composition in the development of type 2 diabetes. Therefore, the sixth chapter discusses the impact of metabolic disorders, such as obesity and type 2 diabetes, on the regulation of lipid species and oxidative stress.

Hiroaki Eshima

Department of International Tourism
Sports Tourism Course
Nagasaki International University
Nagasaki, Japan

Ikuru Miura

Faculty of Sports and Health Science
Fukuoka University
Fukuoka, Japan

Yutaka Matsunaga
Faculty of Human Health
Kurume University
Kurume, Japan

&

Yuki Tomiga
Faculty of Sports and Health Science
Fukuoka University
Fukuoka, Japan

List of Contributors

- Hiroaki Eshima** Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan
- Ikuru Miura** Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan
- Yutaka Matsunaga** Faculty of Human Health, Kurume University, Kurume, Japan
- Yuki Tomiga** Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan

CHAPTER 1**Muscle Glucose Metabolism in Metabolic Diseases****Hiroaki Eshima^{1,*}**¹ *Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan*

Abstract: Metabolic diseases such as obesity and diabetes cause disruption of systemic energy metabolism and are major public health problems, with at least 2 billion people affected worldwide. Skeletal muscle tissue makes a substantial contribution to promoting energy efficiency because it remodels cellular size, composition, and function in response to various nutritional changes. However, metabolic diseases such as impaired insulin sensitivity can dynamically affect the metabolism of skeletal muscle. A deeper understanding of myopathology in metabolic disorders may provide clues for therapeutic strategies to promote skeletal muscle health and improve the overall quality of life. This chapter presents how metabolic diseases *via* cellular mechanisms affect muscle cells and muscle tissue, especially glucose metabolism in skeletal muscle.

Keywords: Diabetes, Glucose, Obesity, Metabolism, Skeletal muscle.

INTRODUCTION

Diabetes and obesity have a high risk of leading to diseases, including myocardial infarction and stroke, which affect life expectancy, and thus therapeutic strategies are needed [1]. A major feature of metabolic disease is insulin resistance. Insulin resistance is associated with obesity and type 2 diabetes mellitus (T2DM). It is generally defined as a reduction in the ability of the body to absorb blood glucose from circulation in response to insulin. Glucose is the main nutrition for energy consumption, but excess blood glucose is an index for obesity and T2DM. Insulin resistance from skeletal muscle is commonly viewed as the critical component of whole-body insulin resistance because the muscle is the most important tissue for insulin-stimulated glucose disposal [2].

Carbohydrates, lipids, and proteins all ultimately break down into glucose and then serve as the primary metabolic fuel in a mammalian cell. Glycogen in skel-

* **Corresponding author Hiroaki Eshima:** Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan; E-mail: heshima@niu.ac.jp

etal muscles contains approximately as much as 50,000 glucose moieties. However, the large increase in muscle glycogen is generally associated with insulin resistance in the glucose transport process [3, 4]. Insulin activates the glycogen synthase pathway, whereas glycogen synthesis in muscle is markedly reduced in T2DM [5, 6]. Despite many years of research, the molecular mechanisms by which metabolic disease promotes insulin resistance in skeletal muscle are not fully understood.

Recent research focused on how lipid species affect glucose metabolism in skeletal muscles. Lipids were also used as molecules to probe the basic mechanisms of ion fragmentation following electron ionization [7]. However, fundamental studies using mass spectrometry analysis of lipids demonstrate that lipid species are associated with insulin resistance in obesity and diabetes [8 - 11]. This chapter presents the cellular and molecular mechanisms of obesity- and diabetes-induced insulin resistance in skeletal muscle.

MUSCLE GLUCOSE TRANSPORTER IN OBESITY AND DIABETES

Glucose is a key metabolic substrate for the whole body. Muscle tissues require glucose as an energy source for adenosine triphosphate (ATP) production [12]. Glucose metabolism starts with transport across the plasma membrane [13]. Skeletal muscles take up glucose in response to insulin stimulation and exercise. The insulin receptor (IR), insulin receptor substrates (IRS), and phosphatidylinositol 3-kinase (PI3K) activation are essential components of the insulin-induced response. Eventually, blood glucose is taken into intramyocellular through glucose transporter 4 (GLUT4) translocation [14, 15]. GLUT4 is an insulin-regulated glucose transporter that is responsible for glucose uptake in muscle. It is mainly located in intracellular vesicles in the absence of insulin [16]. Obesity and T2DM are strongly linked to the development of insulin resistance within the skeletal muscles [17]. In 1975, Kemmer *et al.* demonstrated that the skeletal muscles of obese rats are insulin-resistant with respect to both glucose-transport mechanisms and intracellular pathways of glucose metabolism [18]. Consistent with this, the expression of GLUT4 can explain the insulin-resistant glucose uptake characteristic of dietary-induced obesity [19]. A previous study revealed that transgenic overexpression of GLUT4 enhances glucose tolerance in lean and obese mice [20]. Taken together, increasing muscle GLUT4 content is an important target for improving glucose tolerance in obesity.

The main molecule pathway for glucose uptake through GLUT4 is the PI3K/AKT signaling pathway. The PI3K/AKT pathway is a central regulator in cellular physiology for growth factor signals and critical cellular processes [21]. PI3K and serine/threonine kinase 1 (Akt) signaling is important for insulin-stimulated

glucose uptake in skeletal muscle tissues. AKT phosphorylates are involved in the regulation of GLUT4 translocation [22]. PI3K/AKT signaling pathway exists in various organs, but obesity and T2DM impair PI3K/AKT signaling [22]. Sano *et al.* demonstrated that insulin increases the phosphorylation of AS160 and GLUT4 translocation in 3T3-L1 adipocytes [23]. In human skeletal muscles, exercise increases AS160 phosphorylation without insulin infusion [24]. Similarly, obese rodent muscles decrease glucose uptake with decreased AS160 phosphorylation on Ser588 with or without insulin stimulation [25].

AMP-activated protein kinase (AMPK) increases glucose uptake through PI3K/Akt signaling. For instance, loss of skeletal muscle AMPK exacerbates glucose intolerance and insulin resistance in obese people, resulting in a significant decrease in glucose uptake in skeletal muscles [26]. Indeed, loss of AMPK activity has been observed in the skeletal muscle of patients with obesity and diabetes [27, 28]. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) reportedly activates AMPK and stimulates glucose uptake by skeletal muscle [29], suggesting a drug target to facilitate muscle glucose uptake in obesity and diabetes [30]. Long-term AICAR improves glucose metabolism in insulin-resistant obese mice, which can be explained by effects on muscle glucose uptake [31]. However, a previous report has reported that the stimulatory effects of AICAR on glucose uptake are reduced in older men, irrespective of type 2 diabetes, suggesting that AICAR has only a limited therapeutic effect on older type 2 diabetic skeletal muscles [32].

TBC1D1 and TBC1D4, the two Rab GTPase-activating proteins, are closely related to the GLUT4 translocation to the plasma membrane, resulting in increased glucose uptake [33]. The phosphorylation of TBC1D1 and TBC1D4 has been defined as targets for the AKT and the AMPK [34]. Insulin increases in AS160 phosphorylation in skeletal muscle tissues [35] and cells [36]. Deletion of phosphorylated AS160 exhibits reduced insulin-induced GLUT4 translocation in adipocytes and muscle cells [23, 37]. Therefore, AS160 phosphorylation induces glucose uptake into muscles through the translocation of GLUT4 vesicles. On the other hand, insulin-stimulated AS160 phosphorylation is reduced in T2DM [38]. However, reduced muscle glucose uptake of obesity is not associated with the AKT/AS160 content [39]. Therefore, underlying mechanisms for the impaired glucose uptake in metabolic disease are not completely understood.

In type 1 diabetic rodent models induced streptozocin, NPC43 can effectively increase glucose uptake by activating PI3K, Akt, and AS160 pathways through insulin receptors [40]. Akt and AMPK phosphorylated proteins to vesicle traffic appear to be dependent on linking to small GTPase of the Rab family [41]. When activated, Akt by insulin or muscle contraction phosphorylates AS160 and

The Role of Skeletal Muscles in Metabolic Dysfunction-Associated Steatotic Liver Disease

Ikuru Miura^{1,*}

¹ Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan

Abstract: Skeletal muscles and the liver share functions as metabolic organs, and there are known crosstalk in their pathophysiology. In today's world, where obesity is rampant, many people suffer from metabolic abnormalities associated with obesity, posing a global health issue. This chapter summarizes the latest findings on the crosstalk between metabolic dysfunction-associated steatotic liver disease (MASLD) and skeletal muscles, which starts and progresses in association with obesity and its associated systemic metabolic abnormalities.

Keywords: Muscle-Liver axis, MAFLD/MASH, NAFLD/NASH, Skeletal muscle.

INTRODUCTION

Skeletal muscles are the largest organs in the body, and they have roles in locomotor function and metabolism of glucose and lipids. They also act as endocrine organs, secreting bioactive substances known as myokine. Decreases in muscle mass, such as sarcopenia and metabolic dysfunction, are associated with numerous diseases, including type 2 diabetes, lipid disorders, metabolic dysfunction-associated steatotic liver disease (MASLD), and cognitive impairment, among others [1 - 3]. The skeletal muscle and liver share functions as metabolic organs, contributing to systemic metabolic regulation through mutual cooperation (Muscle-Liver axis). There is a crosstalk between the dysfunction and pathology of skeletal muscle and liver. Regarding this pathophysiological crosstalk, it may be easy to understand that when dysfunction occurs in one organ, the other organ alone must process the same function, placing a significant burden on that organ. This chapter summarizes the relationship between quantitative and qualitative changes in skeletal muscle and the pathophysiology of MASLD, as

* Corresponding author Ikuru Miura: Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan; E-mail: miurai@fukuoka-u.ac.jp

well as introduces the mediators of the muscle-liver axis that have been elucidated thus far.

It should be noted that MASLD is a newly defined concept of a disease introduced in 2023, which redefines previously known conditions such as nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MAFLD). First, I will briefly outline the definitions, name changes, and the process of redefinition for each condition. However, evidence and reviews mentioning MASLD are limited to date. Unless otherwise specified, I will treat these conditions in the chapter as synonymous. However, since the definition of each disease is strictly different, the names of the diseases used in the original texts are used when referring to previous studies.

DEFINITION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

It is known that overweight and obesity induce fat deposition in the liver, which in turn leads to hepatic inflammation and fibrosis. Hepatic inflammation and fibrosis can lead to more serious diseases such as cirrhosis and hepatocellular carcinoma, and their pathogenesis has been attracting attention with the increase in the obese population. Hepatic inflammation and fibrosis based on the fatty liver caused by obesity or overweight were first reported and named “non-alcoholic steatohepatitis (NASH)” by Jurgen Ludwig in 1980. The term “non-alcoholic fatty liver disease (NAFLD)” is used to distinguish non-alcoholic fatty liver (NAFL), which is a benign fatty liver that shows lipid deposits in the liver from NASH, and to describe the progression of the disease from NALF to NASH. NAFLD is used as a disease concept to describe a chronic liver disease that progresses to hepatitis and fibrosis with systemic metabolic abnormalities based on obesity and ectopic fat deposition in the liver without a clear history of alcohol consumption (less than 30g/day in men and 20g/day in women in terms of ethanol). In today's society, the number of obese people continues to increase, and the number of patients with NAFLD is also growing worldwide. It is recognized as one of the most common chronic liver diseases [4, 5].

NAFLD presents two distinct conditions: benign NAFL and malignant NASH. In addition, given that liver biopsy is required for definitive diagnosis, it is unsuitable for the efficient screening of high-risk fatty liver patients in clinical practice. There is also a concern that the relatively low alcohol intake standard may exclude patients with a drinking habit. Therefore, a new disease concept focusing on metabolic abnormalities involved in the progression from fatty liver to hepatitis and fibrosis, “Metabolic dysfunction-associated fatty liver disease (MAFLD)”, was proposed in 2020. In addition to fatty liver, MAFLD is defined

by the presence of obesity or type 2 diabetes or meeting two or more criteria indicating abnormalities in glucose or lipid metabolism. As mentioned above, although NAFLD and MAFLD have different diagnostic criteria, they represent concepts that are shared by many patients in reality. However, when comparing MAFLD with NAFLD, MAFLD allows for the exclusion of low-risk fatty liver patients without metabolic abnormalities while identifying high-risk fatty liver patients with metabolic abnormalities and a history of alcohol consumption. Additionally, since liver biopsy is not required for diagnosis, MAFLD was expected to be a useful disease concept for screening high-risk fatty liver patients. However, many people are resistant to the terms “alcoholic” and “fatty” used in NAFLD and MAFLD, and the problem that there is a group of patients who are excluded from screening in NAFLD and MAFLD remains unresolved. There have always been calls by medical doctors and medical researchers to redefine the disease concept.

Against this background, efforts were made to create a new concept of the disease in 2023 through the cooperation of institutions around the world, led by the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) [6]. The concept of steatotic liver disease (SLD) was proposed as a generic term for fatty liver diseases of various etiologies. These are classified into five categories according to pathogenesis and cause. The concept of MASLD was proposed as a concept similar to the conventional NAFLD or MASLD. MASLD was defined as a fatty liver with an abnormal level of one or more of the following cardiometabolic risk factors (BMI or waist diameter), abnormal glucose metabolism (blood glucose level or HbA1C), blood pressure, blood triglycerides, and blood HDL cholesterol (Fig. 1). In addition, metabolic dysfunction-associated steatohepatitis (MASH) was also proposed as an alternative to conventional NASH. Although MASLD/MASH is expected to replace NAFLD/NASH or MAFLD in clinical practice in the future, it would be more meaningful to treat these disease concepts as synonymous to some extent for the time being in terms of accumulation of scientific knowledge.

MECHANISM OF ONSET AND PROGRESSION OF NASH (MASH): THE MULTIPLE PARALLEL HITS HYPOTHESIS

Although NASH is a serious liver disease that can progress to cirrhosis and hepatocellular carcinoma, there are few preventive and curative measures to date. One reason for this is the complexity of the pathogenesis and progression mechanism. “The multiple parallel hits hypothesis” proposed in 2010 is supported as a mechanism for the onset and progression of NASH [7, 8]. This hypothesis suggests that multiple extrahepatic organ abnormalities are involved in the onset and progression of NASH in parallel hits.

CHAPTER 3

Impact of Nutrition and Exercise on Carbohydrate Metabolism**Yutaka Matsunaga^{1,*}**¹ Faculty of Human Health, Kurume University, Kurume, Japan

Abstract: People consume nutrients such as carbohydrates, fats, proteins, vitamins, and minerals in their diet. Among these, carbohydrates and fats are mainly used by the body as energy. Lipids are stored in the body mainly in the form of triglycerides, whereas carbohydrates are primarily stored in the liver and skeletal muscles in the form of glycogen. Compared to fat, glycogen can be stored in much smaller quantities in the body. Glycogen utilization has also been shown to increase during exercise. When glycogen is depleted, exercise performance is impaired. Glycogen is, therefore, a valuable source of energy, and much research has been conducted on how to store glycogen and how to enhance glycogen recovery after exercise. In addition, managing glucose and glycogen through proper nutrition and exercise training is very important not only for improving athletic performance but also for maintaining and improving health. Therefore, this chapter focuses on the impact of nutrition and exercise on carbohydrate metabolism.

Keywords: Glycogen, Glucose, Liver, Metabolism, Skeletal muscle.

INTRODUCTION

People consume nutrients such as carbohydrates, fats, proteins, vitamins, and minerals in their diet. Among these, carbohydrates and fats are mainly used as energy for the body. Ingested carbohydrates are broken down by digestive enzymes such as amylase and are absorbed primarily in the small intestine. Carbohydrates absorbed in the small intestine are transported throughout the body in the form of glucose. This glucose is used for ATP (adenosine triphosphate) production or stored as glycogen. Glycogen is stored mainly in the liver and skeletal muscle, and the amount is approximately estimated to be 100 g in the liver and 500 g in skeletal muscle, for a total of about 600 g [1, 2].

It has been shown that glucose utilization increases during exercise compared to resting conditions [3]. This increase is due to a greater reliance on the glycolytic

* Corresponding author Yutaka Matsunaga: Faculty of Human Health, Kurume University, Kurume, Japan;
E-mail: matsunaga_yutaka@kurume-u.ac.jp

system for energy production. Carbohydrates provide 4 kcal of energy per gram, but the body can store only a few thousand calories. This is a small amount compared to the vast amount of energy stored in the body in the form of triglycerides. Glycogen is a particularly important energy source because of the limited amount that can be stored. Much research has focused on strategies for pre-exercise glycogen storage and post-exercise glycogen replacement. In addition, managing glucose and glycogen through proper nutrition and exercise training is critical not only for improving athletic performance but also for maintaining and improving health. Therefore, this chapter focuses on the impact of nutrition and exercise on carbohydrate metabolism.

EXERCISE AND GLYCOGEN DEPLETION

During exercise, carbohydrates and lipids are the main sources of energy. Lipids have 9 kcal of energy per gram, while carbohydrates have 4 kcal per gram. Lipids have a high energy density, which has the advantage that when energy is stored in the form of triglycerides, they are less likely to gain weight. However, it takes more effort than carbohydrates to metabolize lipids and use them as energy. Therefore, during exercise, which requires quick movements, more readily available carbohydrates are used. In previous studies, it has been reported that prolonged exercise decreases glycogen in skeletal muscle [4]. Skeletal muscle glycogen is also reduced by brief periods of high-intensity exercise, such as 30 seconds of all-out exercise [5].

The decrease in skeletal muscle glycogen content associated with exercise occurs in an exercise intensity-dependent manner [3, 6, 7]. For example, Van Loon *et al.* examined changes in the percentage of energy substrate utilization during 40, 55, and 75% maximal workload (W_{max}) exercise in elite cyclists. The results showed that at rest, lipid oxidation and carbohydrate oxidation accounted for 56% and 44% of total energy expenditure, respectively, whereas at 40% W_{max} , lipid oxidation and carbohydrate oxidation accounted for 55% and 45%, respectively. At 55% W_{max} , lipid oxidation was 49% and carbohydrate oxidation was 51%, and when exercise intensity was increased to 75% W_{max} , lipid oxidation was 24% and carbohydrate oxidation was 76% [3]. Romijn *et al.* similarly evaluated energy substrate utilization during exercise at 25, 65, and 85% VO_{2max} and reported increased glucose oxidation with increasing exercise intensity [6]. These data indicate that glucose utilization increases with increasing exercise intensity. It has also been reported that glucose tissue uptake increases with increasing exercise intensity and that at 65 and 85% VO_{2max} exercise, carbohydrate oxidation greatly exceeds glucose uptake [6]. In other words, glucose utilization in skeletal muscle increases with exercise, and glycogen is more likely to be depleted than glucose uptake. In fact, it has been reported that glycogen decreases

significantly in competitions such as soccer, in which long periods of running and short periods of sprinting are repeated [8].

Effects of Muscle Glycogen Depletion

Glycogen can be stored in the body in much smaller quantities than fat. For example, Guezennec *et al.* reported that A man whose weight is near 70 kg has approximately 15 kg of fat as triglycerides in adipose tissue, representing about 140,000 kcal [9]. In humans, on the other hand, given that the majority of glycogen is stored in skeletal muscle (~500 g) and liver (~100 g) [1], the amount of carbohydrates in the body is only a few thousand kcal. Also, with exercise, glycogen stores decrease significantly.

So, what are the effects of reduced glycogen in skeletal muscle? In a previous study, Xirouchaki *et al.* examined the impact on exercise capacity in mice in which glycogen synthase was knocked out, specifically in skeletal muscle.

The results showed that exercise performance decreased when skeletal muscle glycogen levels were reduced [10]. There are several factors that contribute to reduced exercise performance when skeletal muscle glycogen levels decrease, but they are not yet fully understood. One possibility is that reduced glycogen levels affect ATP resynthesis in the glycolytic system, which would be a limiting factor in exercise, especially during high-intensity exercise. In addition, glycogen is involved in Na⁺, K⁺, and ATPase activity [11], and reduced skeletal muscle glycogen is involved in Ca²⁺ release from the sarcoplasmic reticulum [12]. Furthermore, it has been reported that reduced Ca²⁺ release leads to reduced muscle tensile strength [13]. Thus, a decrease in skeletal muscle glycogen content may inhibit muscle contraction.

Effects of Liver Glycogen Depletion

The main storage tissues for glycogen are the liver and skeletal muscles, with the liver holding 100 g and skeletal muscles holding 500 g, for a total of about 600 g [1, 2]. Therefore, the liver, like skeletal muscles, stores a large amount of glycogen. The glycogen in skeletal muscles is broken down to produce ATP, which can then be used to contract muscles. On the other hand, the primary role of glycogen in the liver is to supply glucose to extrahepatic tissues and maintain blood glucose levels [14]. When blood glucose levels decrease, the liver acts as a glucose sensor, degrading glycogen and supplying glucose to the blood. The ability of the liver glycogen to maintain blood glucose levels for some time without causing immediate hypoglycemia during fasting is due to the function of liver glycogen. However, liver glycogen stores are also limited. Exercise raises the degradation of liver glycogen [15]. Wahren *et al.* reported that splanchnic

Brain Health in Metabolic Disease and Exercise

Yuki Tomiga^{1,*}

¹ Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan

Abstract: Modern lifestyles, such as a Western diet, excessive food consumption, and physical inactivity, are closely associated with brain health and noncommunicable diseases, including type 2 diabetes. Epidemiological evidence suggests that an unhealthy lifestyle leads to impaired brain health, manifesting in conditions such as depression and anxiety. Conversely, mental illness can contribute to the development of type 2 diabetes. Thus, it has been suggested that there is a bidirectional relationship between brain health and metabolic diseases, but the detailed mechanisms remain unclear.

Exercise is considered the primary choice for the treatment of obesity or type 2 diabetes. This is attributed to the fact that increased physical activity contributes to a reduction in body weight and the accumulation of excess adipose tissue. Furthermore, it has long been recognized that exercise enhances brain health. Recent studies have revealed that, in addition to these indirect effects, exercise exerts its beneficial effects by releasing bioactive substances. This chapter presents how metabolic diseases affect brain health and how exercise mitigates these detrimental effects, focusing particularly on the molecular mechanisms in the brain.

Keywords: Anxiety, Brain, Cognitive function, Diabetes, Depression, Hippocampus, Obesity.

INTRODUCTION

Obesity is defined as an excess of body adiposity. According to a report from the World Health Organization, worldwide obesity has nearly tripled since 1975, and 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. From this situation, in 2023, WHO advocated the *WHO acceleration plan to stop obesity* [1]. Overweight and obesity are central to the risk of metabolic syndrome, predisposing individuals to insulin resistance, hypertension, and dyslipidemia, all of which are risk factors for metabolic syndrome [2], and then progresses to the pathology of type 2 diabetes. Epidemiological research suggests that depression rates are twice as high among persons with diabetes as among

* Corresponding author Yuki Tomiga: Faculty of Sports and Health Science, Fukuoka University, Fukuoka, Japan; E-mail: tomiga0507@gmail.com

persons without diabetes [3]. In addition, diabetes is associated with an increased risk of psychological disturbance, especially for those with more diabetes-related complications [4]. Based on these studies, it has been considered as evidence that diabetes (and its complications) increases the risk of mental disorders. The causal relationship between metabolic and mental disorders remained unclear, but accumulating evidence suggested that it might appear to be bidirectional [5]. It is well known that physical activity, such as regular exercise, is beneficial for our health. It remained unclear whether the effect was simply due to the improvement of obesity or the effect of exercise itself. Very recent studies have revealed that exercise has its effects on the whole body, including the brain, through diverse mechanisms.

This chapter outlines the negative effects of metabolic diseases on brain health, especially in depression and anxiety, and the beneficial effects of exercise in improving them.

IMPAIRED BRAIN HEALTH IN METABOLIC DISEASE

With the recent westernization of diets, obesity has been increasing on a global scale and is already well-known to be a risk factor for various diseases [6]. In the 1980s, the ideal body weight approach was replaced by BMI, and the commonly used cutoffs for overweight (BMI 25–30) and obesity (BMI >30), for both men and women, were adopted to define obesity in adults [7]. Excess energy due to excessive lipid intake leads to obesity and the associated skeletal muscle insulin resistance and impaired glucose tolerance, which are major factors in type 2 diabetes mellitus. Although previous studies on obesity and glucose metabolism have focused on adipocytes [8 - 10] and skeletal muscle [11 - 13], recent studies have revealed that obesity also has important effects on brain function. For example, epidemiological studies reported that Western eating habits and being overweight are associated with reduced hippocampal volume [14, 15]. Western eating habits have also been found to be associated with psychiatric disorders such as depression and anxiety [16]. Insulin resistance is a prediabetic stage. A systematic review revealed a small but significant cross-sectional association between depression and insulin resistance [17]. In a study that investigated the association between metabolic syndrome and mood disorders, metabolic syndrome is associated with depressive symptoms but not anxiety in both men and women, irrespective of overweight/obesity status [18]. Further, patients with diabetes with both minor and major depression are associated with increased mortality [19].

Meanwhile, evidence suggests that a bidirectional relationship, in other words, mental illness, increases the risk of type 2 diabetes [5]. Eaton *et al.* reported in the

90s that major depressive disorder signals an increased risk for the onset of type 2 diabetes [20]. Also, individuals with newly diagnosed diabetes were 30% more likely to have had a previous history of depression compared with people without diabetes [21]. Interestingly, this relationship between mental illness and metabolic dysfunctions is observed not only in adulthood. According to Shomaker *et al.*, children's depressive symptoms were a significant predictor of follow-up HOMA-IR, fasting insulin, and fasting glucose levels [22]. A more recent study reported that persistently high fasting insulin levels from age 9 years were associated with psychosis at 24 years, and puberty-onset body mass index increase was associated with depression at 24 years [23].

In summary, obesity and overweight and the resulting metabolic disorders and psychiatric disorders, including depression, are bidirectional. Furthermore, childhood depression (or metabolic parameters such as high insulin levels) may be a predictor of future metabolic parameters (or depressive symptoms).

IMPAIRED NEUROGENESIS AND MOLECULAR MECHANISMS IN THE BRAIN IN METABOLIC DISEASE

Metabolic disorders are associated with impairment of brain health; however, these regulating mechanisms are not fully understood. In this section, we focus on mature hippocampal neurogenesis and molecular signaling within the hippocampus as the underlying mechanisms. As the hippocampus is a site of structural and functional pathology in most psychiatric disorders, it plays a crucial role in their manifestation. Therefore, a hippocampal-based treatment approach has been proposed to combat the cognitive deficits and mood dysregulation that are hallmarks of psychiatric disorders [24]. Adult hippocampal neurogenesis, the generation of new neurons in the adult dentate gyrus (DG), is an important event for the maintenance or regulation of brain function. Adult hippocampal neurogenesis is first discovered by Joseph Altman in 1963 [25]. In animal studies, mice lacking adult neurogenesis increased response to stress, which elevated blood glucocorticoid corticosterone [26]. Chronic high corticosterone reduces adult hippocampal neurogenesis in both males and females [27]. In addition, the above-mentioned adult neurogenesis-deficient mice also showed increased anxiety and depression-like behaviors [26]. In contrast, antidepressant treatment increased adult hippocampal neurogenesis [28, 29] and reduced depressive behaviors [30].

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophic family of proteins and is one of the key factors that affect cognitive functions and mental illness. BDNF is expressed in the central nervous system and is highly in the limbic area, which is important for effective regulation. BDNF regulates the

Muscle Atrophy and Weakness in Metabolic Disease

Hiroaki Eshima^{1,*}

¹ Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan

Abstract: Obesity and diabetes are associated with changes in skeletal muscle quantity and quality, such as increased ectopic fat, muscle atrophy, and decreased muscle strength. Skeletal muscle tissue is often affected by metabolic insult because it remodels cellular size, composition, and function in response to a variety of nutritional changes. Declining muscle quantity and quality are directly linked to falls and bedriddenness; understanding the intracellular mechanisms may provide clues for therapeutic strategies. How metabolic diseases *via* cellular mechanisms affect muscle quality and muscle quantity are presented in this chapter.

Keywords: Contraction, Calcium, Diabetes, Fiber type, Motor neuron, Myofibrillar, Obesity, Skeletal muscle, Satellite cell.

INTRODUCTION

Skeletal muscle is one of the largest organs in humans and accounts for ~40% of body mass in healthy-weight individuals, which is important for maintaining metabolic health [1]. Carbohydrates and fats are the primary nutrients that provide the necessary energy required during exercise. However, the metabolic insults in the regulation of glucose and lipids cause skeletal muscle abnormalities. As fat increases in the body due to lipid accumulation, the risk of type 2 diabetes mellitus (T2DM) increases, which is associated with insulin resistance in skeletal muscle [2]. Previous studies have focused on the cellular and molecular mechanisms of obesity- and diabetes-induced insulin resistance in skeletal muscle. On the other hand, recent studies have focused on the effect metabolic insult has on the loss of muscle size, strength, and physical function.

Skeletal muscle tissues are heterogeneous in their composition and mainly divided into slow-twitch and fast-twitch myofibers. The differences between slow- and

* Corresponding author Hiroaki Eshima: Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan; E-mail: heshima@niu.ac.jp

fast-twitch fibers are the contractile proteins and types of energy metabolism, such as ATP production from mitochondria [3]. Furthermore, skeletal muscle adapts to numerous stimuli such as exercise, nutrition, disease, and aging, and these responses are manifested through changes in muscle size, fiber-type distribution, and metabolism. In contrast, muscle atrophy and weakness decrease the quality of life and increase the risk of injuries, falls, and the development of diseases. Indeed, diabetes and obesity cause loss of muscle mass and decrease muscle strength [4, 5]. Pharmacologic therapy for muscle loss induced by metabolic disease does not exist, and current diet/exercise therapeutic approaches are often ineffective and/or unfeasible.

This chapter will address skeletal muscle metabolism in metabolic disease through a brief comprehensive summary and describe the potential mechanisms of dysfunction of contractile force (weakness) and muscle atrophy induced by metabolic disease in skeletal muscle.

MUSCLE ATROPHY IN METABOLIC DISEASE

Lipids often ectopically accumulate in non-adipose tissues, including skeletal muscle [6]. Muscle lipids have been extensively studied in the context of metabolism, such as insulin sensitivity [7 - 9]. However, muscle lipid overload appears to affect not only metabolism but also muscle quantity, such as muscle maintenance and regeneration. There is evidence that diabetic myopathy is unfavorable for muscle growth and regeneration [10 - 12]. The loss of muscle mass in metabolic disorders is partly accounted for by an altered balance between synthesis and degradation in protein [13, 14]. Previous studies have reported that obesity causes the loss of muscle mass due to a decrease in muscle protein synthase and activation of protein degradation [15 - 17]. On the other hand, a high-fat diet (HFD) does not change the muscle protein synthase [18]. The lipid overload increases protein synthesis in skeletal muscle in rodent models [19]. These findings suggest that the mechanism underlying the muscle atrophy in metabolic disorders has not been fully elucidated.

Mechanisms that may contribute to lower muscle mass of metabolic disease can include decreases in the satellite cell. A previous study has reported that the differentiation of myoblasts is impaired in patients with diabetes, suggesting that one of the underlying causes of muscle loss [20]. Diabetic myoblasts had a reduced ability to differentiate into skeletal muscles, whereas administration of myogenic oligodeoxynucleotide improved skeletal muscle differentiation exacerbated by diabetes [20]. In obese rodent models, obese Zucker rats reduce the number of satellite cells, which may be a factor that contributes to the reduced muscle mass [12]. Interestingly, satellite cell proliferation can be restored with

compensatory loading with surgery. Similar results were obtained in mice models of T2DM, and impaired muscle regeneration in T2DM mice was associated with reduced accumulation of macrophage and angiogenesis [21]. This cytokine was increased in muscle in patients with T2DM, suggesting a possible mechanism by which muscle function is compromised in diabetes [22]. These findings suggest that metabolic disease severity will mainly influence the functions of satellite cells.

Insulin resistance is associated with increased lipolysis and the release of free fatty acids from adipose tissue, which may lead to the inhibition of muscle regeneration through the growth hormone/insulin growth factor-1 [5, 23]. Furthermore, oxidative stress, mitochondrial dysfunction, inflammation, and protein degradation pathways have been implicated in muscle atrophy and weakness. Indeed, these factors are increased in skeletal muscle of metabolic diseases [24]. For example, metformin is a commonly prescribed medication for T2DM patients due to decreased hepatic glucose production and intestinal absorption of glucose. A previous study showed that metformin ameliorates muscle atrophy due to decreased muscle atrophy-related genes in HFD-induced obese rats [25]. However, a long-term administration of metformin causes accelerates muscle atrophy through the activation of phosphorylated AMPK in *db/db* mice [26]. Metformin should be prescribed to patients with T2DM because of its great efficacy in reducing hyperglycemia and other diabetes-related complications, but there is no effective treatment for muscle wasting that has been established. Metformin might induce muscle atrophy that is regulated in an AMPK-dependent manner [27 - 30]. AMPK is not only associated with the glucose transporter system but also inhibits anabolic processes such as protein synthesis and increases protein degradation and autophagy [31]. Thus, it is skeptical whether antidiabetic drugs are necessarily effective against muscle atrophy.

MUSCLE CONTRACTILE ADAPTATION IN METABOLIC DISEASE

Rodent studies demonstrate that obesity induced by HFD impairs contractile function with electrical stimulation, enhanced fatigability, and increased muscle fragility [32 - 34]. A previous study demonstrated that middle-aged mice fed HFD exhibited decreased grip strength [35]. Consistent with this, another study also shows that the contractile force was lower in aged mice fed HFD [36]. These findings suggest that the synergistic effects of obesity and aging may exacerbate muscle contractile dysfunction. Consistent with these findings, Eshima *et al.* recently demonstrated that chronic HFD feeding significantly reduced contractile force in fast-twitch dominant muscles but not slow-twitch dominant muscle in aged skeletal muscle [33] (Fig. 1).

The Cellular Mechanism in Skeletal Muscle in Metabolic Disease: Lipid Species and Oxidative Stress

Hiroaki Eshima^{1,*}

¹ Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan

Abstract: Obesity and diabetes impair skeletal muscle metabolism, muscle atrophy, and contractile function, but the intracellular mechanisms have not been clarified fully. Increasing evidence suggests that oxidative stress is associated with obesity and diabetes. Depending on the pathological condition, stress may be affected to a greater extent. Muscle oxidative stress has been implicated in lipid species composition in type 2 diabetes. This chapter discusses the impact of metabolic disease on the regulation of lipid species and oxidative stress.

Keywords: Ferroptosis, Lipid species, Oxidative stress, Phospholipid, Skeletal muscle.

INTRODUCTION

Under obesogenic conditions such as feeding a high-fat diet (HFD), the excessive abundance of fat leads to intramyocellular (IMCL) accumulation [1]. IMCL disrupts muscle function, resulting in muscle atrophy in obese [2, 3] and diabetic mice [4]. These results from IMCL accumulation are associated with increased reactive oxygen species (ROS) production that can compromise the antioxidant defense system of skeletal muscle [5]. However, the specific effect of lipid species on oxidative stress in skeletal muscle has not been clarified fully.

Oxidative stress is important for skeletal muscle atrophy [6]. For example, long-term inactivity, such as tail suspension, immobilization, and small cage housing, promote oxidative stress and result in muscle atrophy [7 - 9]. This inactivity-induced muscle atrophy increases intracellular ROS production. Recent studies have indicated that redox signaling is an important regulator of cell signaling pat-

* **Corresponding author Hiroaki Eshima:** Department of International Tourism, Sports Tourism Course, Nagasaki International University, Nagasaki, Japan; E-mail: heshima@niu.ac.jp

ways [10]. Similar to these findings, increased ROS production is an important signal for muscle atrophy induced by aging [11] and cancer [12]. Recent evidence indicates obesity and diabetes induce ROS production [13 - 15], suggesting that metabolic imbalance is linked to dysfunction of the cellular redox system.

The excess lipids are susceptible to oxidation induced by free radicals. Lipid hydroperoxides (LOOH) are one of the primary products of lipid hydroperoxidation and induce oxidative stress. Recently, Stockwell identified that ferroptosis is a novel cell death mechanism characterized by iron-dependent lipid peroxidation [16]. Ferroptosis is associated with a variety of diseases, including cancer, kidney diseases, atherosclerosis, and liver diseases, suggesting that ferroptosis can provide insights and treatment strategies for metabolic diseases [17].

In this chapter, we will discuss the evidence that oxidative stress, particularly lipid peroxidation, contributes to the cell signaling pathways for skeletal muscle homeostasis.

LIPID SPECIES IN SKELETAL MUSCLE

Lipids act as structural components of cell membranes and energy storage sources and participate in signaling pathways. They are also ubiquitous in the organism and play diverse biochemical and physiological functions. Lipid species are present in many classes and can transduce signals to influence cell function (Table 1).

Table 1. Categories of lipid molecular species.

Category	Specific Lipid Species
Fatty acyls	Fatty acids, elcosanoids, endocannabinoids
Glycerolipids	TAG, diacylglycerols
Glycerophospholipid	PC, PE, PI, PS, PG, PA, CL
Sphingolipids	Sphingomyelin, sulfatides, sphingosine, ceramides, ganglioside
Sterol lipids	Cholesterol, estradiol, testosterone, bile acids
Prenol lipids	Farnesol, dolichols, vitamin K
Saccharolipids	Lipid A, acyltrehaloses
Polyketides	Aflatoxins, tetracyclines, erythromycin

In metabolic disease, obese and type 2 diabetes mellitus (T2DM) patients increase concentration of plasma free fatty acid (FFA) [18]. An increased FFA was observed in skeletal muscles from obese rodents [19 - 21] and in obese and T2DM

patients [22, 23]. Plasma FFA enters intramyocellular lipids via protein transporters, such as fatty acid translocase, fatty acid binding protein, and fatty acid transport protein family [24]. Then, fatty acids attach coenzyme A in a reaction catalyzed by acyl-Co synthase and formatted of long-chain acyl-CoA. These are used as a substrate in *de novo* synthesis of other lipids, including triacylglycerols (TAG), diacylglycerols (DAG), and ceramides [25, 26].

In skeletal muscle, a previous study demonstrates that lipid extracts using mass spectrometry analysis have the presence of lipid species, including phospholipids, sphingolipids, and cholesterol esters [27]. The main fatty acid is TAG, and most extracellular-derived fatty acids enter the pool of intracellular TAG [28, 29]. Obesity generally changes lipid species content, including fatty acids of phospholipid and triglyceride [30, 31] (Figs. 1-3). Particularly, obese muscle exhibits increased polyunsaturated (PUFA) from phospholipid and triglyceride fractions [31]. Indeed, analyzing fatty acid-related metabolism, many genes are significantly changed in obese muscle. Consistent with this, obesity increases the fatty acid of phospholipid molecular species.




Fig. (1). Experimental design from a previous study. Animals began HFD at 5 and 12 weeks; two cohorts were administered STZ to induce a T2D phenotype. At 16 weeks, a cohort of HFD and HFD-STZ mice were placed on the standard diet (SD) for 8 weeks. From [32].

In humans, triglyceride and phospholipid content in skeletal muscle have been linked to insulin sensitivity [33 - 35]. Indeed, skeletal muscle phospholipids are inversely related to body fat [35] (Fig. 4). Skeletal muscles are also influenced by

SUBJECT INDEX

A

Abdominal cavity 55
 Ablation of sarcolipin 7
 Abnormalities 18, 22, 50
 behavioral 50
 multiple extrahepatic organ 18
 Absorption 39, 40, 64
 intestinal 64
 sugar 40
 Accumulation, excessive visceral fat 23
 Acid 19, 24, 55, 64, 77, 79, 81
 bile 77
 free fatty (FFA) 19, 24, 55, 64, 77
 hypochlorous 79, 81
 palmitic 24
 Action 6, 40
 glucose uptake/insulin 6
 synergistic 40
 Activation, induced 4
 Acute supine cycling exercise 51
 Acyltrehaloses 77
 Adenosine triphosphate 2, 33
 Adipokine 55
 Adipose tissue 5, 19, 23, 24, 35, 47, 55, 64
 visceral 19
 Aerobic exercise 51, 53
 Aflatoxins 77
 Age-related loss 69
 AKT phosphorylates 3
 Alzheimer's disease 50
 Ammonia 24, 25
 concentrations 24
 metabolize 24
 AMP-activated protein kinase 3
 AMPK 3, 4, 6, 64
 activity 3
 complexes activator 6
 phosphorylated 64
 signaling 4
 Anabolic processes 64
 Angiogenesis 64

Anti-apoptosis 53
 Anti-depressants 52
 Anti-inflammatory disorders 27
 Antidiabetic drugs 64
 Anxiety 47, 48, 51, 53
 Atherosclerosis 77
 ATP 2, 7, 33, 35
 -dependent transport 7
 ATPase activity 35

B

Bacteria, intestinal 25
 BDNF 50, 52
 hippocampal 50, 52
 protein expression 52
 Behaviors, reduced depressive 49
 Bioactive substances 26, 47, 54
 releasing 47
 Blood 18, 41, 54
 -brain barrier 54
 glucose concentration 41
 HDL cholesterol 18
 pressure 18
 triglycerides 18
 Body adiposity 47
 Brain 47, 48, 49, 51, 52, 53, 54
 -derived neurotrophic factor (BDNF) 49,
 51, 52, 53, 54
 health, impaired 47, 48
 murine 52
 Branched-chain amino acids (BCAAs) 24

C

Ca-ATPase activity 7
 Ca²⁺ release, reduced 35
 Calcium flux 82
 Caloric restriction 53
 Carbohydrate(s) 1, 33, 34, 35, 36, 37, 38, 39,
 40, 41, 42, 62
 amount of 35, 36, 38

- consuming 41
 - consumption 38
 - diet 36
 - metabolism 42
 - oxidation 34
 - Carbohydrate intake 38, 39, 40
 - augmenting 40
 - Cardiovascular diseases 6, 21, 54
 - Casein hydrolysate 41
 - Ceiling effect 38
 - Cell(s) 1, 25, 26, 54, 63
 - immune 25, 26
 - mammalian 1
 - neural progenitor 54
 - non-parenchymal 25
 - proliferation, satellite 63
 - Cell death 6, 24, 26, 50, 77, 82
 - iron-dependent 82
 - mechanism, novel 77
 - neuronal 50
 - Cerebral cortical BDNFs 52
 - Chronic 49, 54
 - high corticosterone 49
 - obstructive pulmonary disease 54
 - Cirrhosis 17, 18, 21, 24, 25, 26
 - Cognitive 53, 54
 - disorders 54
 - dysfunctions 53
 - Cognitive functions 47, 49, 50, 51, 52
 - impaired 50
 - Cold stress 85
 - Contractile dysfunction 64, 65, 67, 69, 71, 85
 - Contractile force 63, 64, 65, 69
 - reduced 64, 69
 - Contractile function 64, 67, 76, 70, 71
 - impaired 70, 71
 - Control 5, 22, 24, 65
 - glucose metabolism 22
 - normalize glycemic 5
 - Coronary heart disease 54
 - CTSB level 54
 - Cystine import 84
 - Cytokine 55, 64
 - exercise-induced adipose tissue-derived 55
- D**
- Damage 6, 69, 82, 85
 - cell 82
 - neuromuscular junction 69
 - oxidative 85
 - De novo* lipid synthesis 6
 - Deficits, cognitive 49, 50
 - Dentate gyrus (DG) 49, 50, 51, 54
 - Depression 47, 48, 49, 51, 53
 - Depressive-like behaviors 52, 53, 54
 - recovered shortening-induced 53
 - reduced 54
 - Diabetes 1, 2, 3, 5, 6, 8, 9, 47, 48, 49, 54, 62, 63, 65, 69, 76, 77, 84
 - and obesity 1, 63, 65
 - diagnosed 49
 - management of 5, 84
 - mellitus 1, 48, 62, 77
 - Diabetic 63, 65
 - myoblasts 63
 - myopathy 63, 65
 - Diacylglycerols 6, 77, 78
 - Diet 33, 36, 48, 70, 79
 - high-carbohydrate 36
 - low-fat 70
 - Dietary 2, 22, 41, 53
 - glucose 22
 - induced obesity 2
 - modification 41
 - obesity 53
 - Digestion, enhancing 39
 - Digestive enzymes 33, 40
 - DNA methylation 52
 - Downstream effector 82
 - Dysfunction 16, 63, 52, 54, 55, 77
 - impaired exercise-related cognitive 54
 - metabolic disorders-related brain 52, 55
 - Dysfunctional insulin pathways 5
 - Dyslipidemia 47
- E**
- Eccentric exercise 5
 - EDL muscles 66
 - Effects 35, 50, 55
 - ameliorative 55
 - neuroprotective 50
 - of liver glycogen depletion 35
 - of muscle glycogen depletion 35
 - Elcosanoids 77
 - Electron ionization 2
 - Elevated blood glucocorticoid corticosterone 49
 - Endocannabinoids 77

Subject Index

Endoplasmic reticulum stress (ERS) 53
Energy 1, 4, 19, 22, 24, 33, 34, 37, 41, 42, 62, 77
 consumption 1
 deficiency 19
 depletion 4
 production 34, 37
 storage sources 77
 substrate utilization 34, 41
Energy metabolism 1, 63
 systemic 1
ERS, excessive hippocampal 53
Erythromycin 77
Excessive 4, 7, 34, 36, 37, 39, 52
 obesity 7
 capacity test 36
 ingestion 39
 intensity 4, 34
 sessions 37
 therapy 52
Exercise training 5, 33, 34, 37, 40, 41, 42, 51, 52, 53
 aerobic 51
 effects 52
Extrahepatic tissues 35

F

Fast-twitch 62, 65
 glycolytic 65
 myofibers 62
Fat 17, 20, 22, 27, 36
 adaptation 36
 deposition 17, 20, 22, 27
 diet 36
Fatigability, enhanced 64
Fatty acid(s) 6, 7, 24, 53, 77, 78
 binding protein 78
 influx 24
 synthase (FAS) 7
 translocase 78
Fatty liver, non-alcoholic 17
Feeding, chronic HFD 64
Ferroptosis 76, 77, 82, 84, 85
 coined 82
 inducers 84
 inhibitors 84
 pathway 85
Fiber(s) 63
 fast-twitch 63

Skeletal Muscle Health in Metabolic Diseases 93

-type distribution 63
Fibrosis 17, 21, 24, 26, 54
 cystic 54
Fuel, primary metabolic 1
Function 1, 4, 16, 21, 22, 25, 26, 27, 40, 50, 62, 64, 67, 71, 77, 82, 85
 absorptive 40
 anti-inflammatory 27
 neuronal 50
 physiological 77

G

Gait tests 22
Ganglioside 77
Gastric emptying rate 40
Gastrocnemius muscles 83
Gastrointestinal discomfort 39
Gene expression 52, 54, 82
 elevated Fndc5 54
 increased hippocampal Fndc5 54
 regulating 52
Genes, atrophy-related 64
Genetic loss of AMPK function in skeletal muscle 6
Glucocorticoids 50
Glucose 1, 2, 4, 7, 16, 18, 22, 23, 33, 35, 38, 39, 41, 42, 62, 64
 -6-phosphatase 22
 absorption 39
 intolerance 7
 production, decreased hepatic 64
 sensor 35
 transport process 2
 transporter system 64
Glucose disposal 1, 6
 insulin-stimulated 1
Glucose homeostasis 23, 84
 systemic 23
Glucose metabolism 1, 2, 3, 4, 6, 18, 22, 24, 48, 55
 abnormal 18, 24
 basal systemic 6
Glucose tolerance 2, 5, 48, 55
 impaired 48
 improved HFD-induced 55
Glucose transporter 2, 23
 insulin-regulated 2
Glucose uptake 2, 3, 4, 5, 6, 7, 9, 34, 39, 40, 41

exercise-induced 4, 6
 insulin-independent 4
 insulin-resistant 2
 insulin-stimulated 7
 Glucose utilization 22, 24, 33, 34
 insulin-mediated systemic 22
 GLUT4 4, 41
 protein 41
 trafficking 4
 GLUT4 content 2, 5
 increasing muscle 2
 GLUT4 translocation 3, 5, 6
 and glucose uptake 6
 reduced insulin-induced 3
 Glutathione peroxidase 82, 83
 Glycemic index (GI) 41
 Glycerophospholipid 77
 Glycogen 1, 2, 22, 24, 33, 34, 35, 36, 37, 38,
 40, 41, 42
 body replenishes 37
 reduced 35
 restore 40
 degradation 24
 depletion 34, 36
 resynthesis 38, 41
 synthase 35
 synthase pathway 2
 synthesis 2, 37, 38, 41
 degrading 22, 35
 Glycogenesis 36, 37, 41
 Glycolytic pathway 41
 Growth factor signals 2

H

Health 51, 84
 mental 51
 worsened metabolic 84
 Heart failure 6, 54
 Hepatic 17, 19, 20, 21, 24, 25, 26, 27
 fibrosis 20, 21, 25, 26, 27
 inflammation 17, 19, 21, 24, 25, 26
 Hepatic steatosis 20, 24, 27
 advanced 27
 Hepatic stellate cells (HSCs) 24, 25, 26, 27
 Hepatitis 17, 21
 Hepatocellular carcinoma 17, 18
 Hepatocytes 27
 Hippocampal-based treatment approach 49
 Homeostasis 22, 68

Hormones, elevated adrenal steroid 50
 Hyperammonemia 24
 Hyperglycemia 24
 Hyperlipidemia 53
 Hypertension 47, 54
 Hypoglycemia 35, 36
 Hypothermia 7

I

Impairments 16, 49, 50, 51, 67, 82
 cognitive 16
 functional 50
 reversed stress-induced 51
 Induction, transcriptional 50
 Inflammation 6, 20, 22, 23, 25, 26, 27, 50, 64,
 84
 chronic 25, 26, 50
 hippocampal 50
 obesity-induced 25
 peripheral 6
 Inflammatory 19, 23, 25, 26, 27, 50
 cytokines 19, 23, 26, 27, 50
 signals, activating 25
 Insulin 1, 2, 3, 4, 6, 9, 23, 24, 39, 41, 42, 49
 acts on skeletal muscle and liver 23
 concentrations 42
 fasting 49
 -glucose transporter 23
 hypersecretion 41
 -independent mechanisms 4
 infusion 3
 secretion 39
 uptake-induced 4
 Insulin resistance 1, 2, 3, 5, 6, 7, 19, 20, 22,
 23, 25, 47, 48, 62, 64
 deteriorates 6
 diabetes-induced 2, 62
 obesity-induced 22
 Intracellular pathways 2
 Intramyocellular lipids via protein transporters
 78
 Irisin secretion 27
 Isometric tension 65

K

Kupffer cells 25

Subject Index

L

Lipid(s) 1, 2, 6, 9, 16, 17, 18, 27, 33, 34, 36, 37, 62, 77, 78, 81, 82
accumulation 6, 9, 62
deposits 17
disorders 16
intramyocellular 6
metabolism 18
metabolize 34
oxidation 34
oxidized 82
peroxide 81
synthesis 27
utilization 36
Lipid peroxidation 77, 84
iron-dependent 77
Lipopolysaccharides 19, 25
Lipototoxicity 24
Liver 17, 18, 20, 21, 22, 25, 27, 36
biopsy 17, 18, 20
glucose production 36
lesions, progression of 20, 21, 22, 25, 27
pathology 20
Liver disease 6, 17, 18, 21, 26, 77
chronic 17, 21
fatty 18
metabolic dysfunction-associated fatty 17
nonalcoholic fatty 6, 17
Liver glycogen 35, 36, 39
depletion 35
recovery 39
stores 35, 36

M

Mechanisms, glucose-transport 2
Memory 53, 55
functions, impaired spatial 53
retention 55
Mental 47, 48, 49
disorders 48
illness 47, 48, 49
Metabolic 1, 5, 9, 18, 24, 27, 47, 48, 49, 53, 55, 63, 71, 82, 85
adaptations of skeletal muscle 24
diseases, systemic 27
disorders 1, 9, 49, 53, 55, 63, 71, 82, 85
dysfunction-associated steatohepatitis 18
pathway dysregulations 5

Skeletal Muscle Health in Metabolic Diseases 95

syndrome 47, 48, 53
Metabolic abnormalities 16, 17, 18, 20, 22
associated systemic 16
systemic 17
Metabolism, oxidative 7, 82
Microbiota, intestinal 19
Mitochondria 22, 24, 37, 54, 63
abnormal skeletal muscle 22
biogenesis 54
Mood disorders 48
Multiple sclerosis 53
Muscle atrophy 19, 20, 27, 76, 84
age-related 19
metabolic insult-induced 84
skeletal 19, 20, 27, 76
Muscle glucose transporter 2, 4, 5
Muscle glycogen 2, 22, 35
reduced skeletal 35
Musculo-skeletal disorders 54
Myeloperoxidase 81
Myoblast proliferation 25
Myocardial infarction 1
Myosteatorosis 20, 21, 23

N

Neurogenesis 51
Neurological diseases 53
Neuronal messenger 50
Non-adipose tissues 63

O

Organs, largest glucose-processing 23
Osteoarthritis 54
Osteoporosis 54
Ovarian syndrome 53
Oxidative stress 22, 26, 85
increased 22
inducing 26
injury 85
Oxidoreductase enzymes 79

P

Parkinson's disease 53
Pathologies, hepatic 26
Protein(s) 24, 40, 63, 64
contractile 63
degradation 63, 64

hydrolysate 40
synthesis 24, 63, 64
Proteolysis 24, 82
Psychiatric 48, 49, 51, 53
diseases 53
disorders 48, 49, 51
Pulmonary diseases 54

R

Rab GTPase-activating proteins 3, 4
Reactive oxidative species (ROS) 24, 26, 76,
79, 82, 83, 84
Renal anemia 6
Rheumatoid arthritis 54

S

Sarcopenia 6, 16, 19, 20, 21, 24, 25, 65, 69,
82, 83
Sarcopenic obesity 69
Sarcoplasmic reticulum (SR) 35, 67
Schizophrenia 53
Shivering thermogenic mechanisms 84
Signal, potential lipid 82
Signaling 53, 55, 66, 76
cellular 66
enhanced nitric oxide 53
lactate 55
redox 76
Signaling pathways 4, 52, 77
insulin-independent 4
Skeletal muscle 3, 5, 9, 19, 20, 21, 25, 26, 39,
40, 62, 64, 66, 67, 77, 78, 83
abnormalities 62
aged 64
biopsy samples 83
catabolism 20
diabetic 3, 67
dysfunction exacerbate 26
glucose uptake 39
glucose uptake in 3, 5, 9
homeostasis 77
lesions 25
mass 19, 20, 21, 22, 25, 26
membrane 66
pathology 19
phospholipids 78
protein synthesis 40
Spatial memory 51, 53

impaired 53
Sphingolipids 77, 78
Sphingomyelin 7, 77
Sphingosine kinase 6
Steatotic liver disease 17, 18, 19, 21, 23, 25,
27
Sterol lipids 77
Stress 24, 49, 51, 52, 53, 76
hippocampal endoplasmic reticulum 53
oxidant 24
Superoxide dismutase 81
Synaptic protein synaptophysin 53
Synthase 50, 63
muscle protein 63
System 35, 37, 50, 76, 77
antioxidant defense 76
cellular redox 77
glycolytic 35, 37
nitroergic 50

T

Testosterone 77
Transcription factors 27
Transduce signals 77
Transforming growth factor (TGF) 26, 55
Transmembrane protein 7
Treadmill exercise, moderate-intensity 51
Treatment, antidepressant 49
Triacylglycerols 78
Triglyceride 78, 79
content 79
fractions 78
TRKB signaling 50, 54, 66
Tropomyosin 66
-related kinase 50
Tumor necrosis factor (TNF) 26, 50



Hiroaki Eshima

Hiroaki Eshima is an assistant professor in the Department of International Tourism at Nagasaki International University in Japan. In 2015, he got a Ph.D. at the University of Electro-Communications and was training as a postdoctoral researcher at Juntendo University, Department of Endocrinology (Japan). Then he joined the Funai Lab in the Molecular Medicine Program at the University of Utah. Currently, he has been working as principal investigator since 2021. His interest lies in how metabolic insults affect physiological function. He has developed various metabolic disorder models in obesity, diabetes, and elderly rodents and has interest in identifying novel, lipidology-based therapeutic strategies to improve cellular homeostasis.